Literature DB >> 32929569

Body mass index (BMI) and benefit from adjuvant chemotherapy in breast cancer: is it enough?

Michela Palleschi1, Emanuela Scarpi1, Chiara Casadei2.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32929569     DOI： 10.1007/s10549-020-05923-9

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN： 0167-6806            Impact factor:   4.872


× No keyword cloud information.
  3 in total

1.  Body Composition as a Predictor of Toxicity in Patients Receiving Anthracycline and Taxane-Based Chemotherapy for Early-Stage Breast Cancer.

Authors:  Shlomit Strulov Shachar; Allison M Deal; Marc Weinberg; Grant R Williams; Kirsten A Nyrop; Karteek Popuri; Seul Ki Choi; Hyman B Muss
Journal:  Clin Cancer Res       Date:  2017-01-31       Impact factor: 12.531

2.  Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Nonmetastatic Breast Cancer.

Authors:  Bette J Caan; Elizabeth M Cespedes Feliciano; Carla M Prado; Stacey Alexeeff; Candyce H Kroenke; Patrick Bradshaw; Charles P Quesenberry; Erin K Weltzien; Adrienne L Castillo; Taiwo A Olobatuyi; Wendy Y Chen
Journal:  JAMA Oncol       Date:  2018-06-01       Impact factor: 31.777

3.  Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass Index.

Authors:  Christine Desmedt; Marco Fornili; Florian Clatot; Romano Demicheli; Davide De Bortoli; Angelo Di Leo; Giuseppe Viale; Evandro de Azambuja; John Crown; Prudence A Francis; Christos Sotiriou; Martine Piccart; Elia Biganzoli
Journal:  J Clin Oncol       Date:  2020-07-02       Impact factor: 44.544
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.